The journey from hypothesis to reality on inflammation in CVD
Video navigation menu
- Should we screen for inflammation in patients? 0:30
- Beyond statins, what can we do to lower inflammation? 2:49
- Why haven't we adopted established anti-inflammatory therapies? 5:52
- Conclusion 7:17
This discussion by Peter Libby and Paul Ridker is part of a series titled "Inflammation: The next therapeutic frontier in targeting cardiovascular risk". This series consists of an introduction, three lectures and a discussion in which four experts in this field will bring you up to date on the role of inflammation in atherosclerosis and how to translate findings from science and clinical trials into practice.
Peter Libby is a cardiovascular medicine specialist at Brigham and Women’s Hospital and the Mallinckrodt Professor of Medicine at Harvard Medical School, Boston, MA, USA.
Paul M Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston, MA, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Novo Nordisk.